Johnson & Johnson (JNJ) Earns “Outperform” Rating from Wells Fargo & Co

Wells Fargo & Co reissued their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a report published on Monday morning, The Fly reports. Wells Fargo & Co currently has a $157.00 price objective on the stock, up from their previous price objective of $152.00.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Johnson & Johnson from a hold rating to a sell rating in a report on Wednesday, January 16th. Barclays reissued an equal weight rating and set a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Credit Suisse Group lifted their target price on Johnson & Johnson from $151.00 to $152.00 and gave the stock an outperform rating in a report on Wednesday, April 17th. Citigroup lifted their target price on Johnson & Johnson from $139.00 to $147.00 and gave the stock a neutral rating in a report on Monday, February 25th. Finally, Raymond James lifted their target price on Johnson & Johnson from $145.00 to $147.00 and gave the stock an outperform rating in a report on Wednesday, April 17th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $146.90.

Shares of Johnson & Johnson stock opened at $138.73 on Monday. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The firm has a market cap of $381.21 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 2.46 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The business had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter last year, the firm posted $2.06 EPS. The company’s quarterly revenue was up .1% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th will be issued a dividend of $0.95 per share. The ex-dividend date is Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.74%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. C J Advisory Inc bought a new position in Johnson & Johnson in the first quarter valued at about $33,000. Evolution Wealth Advisors LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. Crewe Advisors LLC grew its position in Johnson & Johnson by 75.0% in the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after acquiring an additional 150 shares during the last quarter. Horan Securities Inc. grew its holdings in shares of Johnson & Johnson by 122.3% during the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after purchasing an additional 241 shares during the last quarter. Finally, First Bank & Trust grew its holdings in shares of Johnson & Johnson by 30.4% during the first quarter. First Bank & Trust now owns 399 shares of the company’s stock worth $56,000 after purchasing an additional 93 shares during the last quarter. Institutional investors own 67.20% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Why is momentum important to successful trading?

The Fly

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.